Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
PBMs, let's say they orchestrate a black box of a financial system where they mix up rebates and some of that goes back to plan sponsors
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)
Would you be willing to submit a prior authorization if needed? Your doctors office may have experience with your insurance company and know how receptive they are to GLP-1 coverage
Fasting blood glucose levels were higher in both STZ and STZ + LEO mice than in the control group (no STZ injection)
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
